AbbVie’s “pain” is Bristol Myers Squibb’s “gain,” says Truist Securities analyst Srikripa Devarakonda.
Media
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
- November 12, 2024
- 3 Views